Clinical Research Directory
Browse clinical research sites, groups, and studies.
Asian Diabetes Outcomes Prevention Trial
Sponsor: National Heart Centre Singapore
Summary
The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2400
Start Date
2019-07-01
Completion Date
2034-06-30
Last Updated
2021-04-30
Healthy Volunteers
No
Conditions
Interventions
Renin-angiotensin-aldosterone system inhibitors
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Beta blocker
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Locations (1)
Singapore General Hospital (SGH)
Singapore, Singapore